Comparing the current results to its competitors, Assertio Holdings Inc reported Revenue decrease in the 1 quarter 2026 year on year by -62.5 %, despite the revenue increase by the most of its competitors of 78.65 %, recorded in the same quarter.
Assertio Holdings Inc 's Comment on Competition and Industry Peers
The company faces competition from generic versions of its INDOCIN products, resulting in a decline in net product sales and loss of market share. Additional generic competition may emerge from other drug companies interacting with the FDA regarding indomethacin. Competition also includes hospitals and institutions, such as a 503B outsourcing facility compounding indomethacin suppositories, which the company believes is violating regulatory requirements. The pharmaceutical and biological product industry is highly competitive, with many principal competitors possessing greater financial, sales, marketing, personnel, and research and development resources. Competing products under development or already marketed may prove superior and achieve greater commercial acceptance.
September 10, 2025
: Assertio Holdings, Inc., a prominent pharmaceutical company, is poised to present new findings from a real-world evidence study concerning SYMPAZAN (clobazam) Oral Film at the 150th Annual Meeting of the American Neurological Association. This study underscores the clinical and commercial potential of SYMPAZAN in addressing neurological conditions. However, despite this promising clinical advancement, Assertio faces economic pressures as reported in their Q2 2025 financial outcomes. This article explores the clinical implications of the SYMPAZAN study in parallel with Assertio s financial landscape, offering insights into the challenges and opportunities the company faces.Assertio Holdings, Inc. is an enti...
December 13, 2024
: The therapeutic landscape for oncology patients necessitates innovative solutions that ensure efficacy, safety, and practicality in the administration of supportive care treatments. In an effort to enhance patient convenience, Assertio Holdings Inc conducted a clinical study evaluating the same-day dosing efficacy of Rolvedon (eflapegrastim-xnst) against the traditional next-day dosing schedules. The results indicated comparable clinical outcomes between the two dosing strategies, presenting an opportunity for heightened flexibility in patient management. However, despite this clinical success, Assertio experienced a notable revenue decline in the third quarter of 2024, starkly contrasting the financial gr...
October 4, 2024
In recent developments, Assertio Holdings, Inc. has disclosed the approval of inducement grants in compliance with NASDAQ Listing Rule 5635(c)(4). While these inducement grants typically aim to attract and retain essential personnel, Assertio s latest financial performance sheds light on the considerable challenges the organization faces, particularly regarding its return on assets (ROA).For the 12-month period culminating at the end of the second quarter of 2024, Assertio Holdings recorded a cumulative net loss amounting to $345 million. Such a substantial financial deficit correspondingly led to an ROA of -112.43%, a stark figure that reflects both operational and financial obstacles. The negative return o...
Acadia Pharmaceuticals Inc's business model centers around the research, development, and commercialization of innovative medicines for diseases related to the central nervous system. They collaborate with a network of partners and employ a combination of in-house research and licensing agreements to discover and develop drug candidates. Their primary revenue stream comes from the sales of approved products, with a focus on providing effective therapeutic options for patients with unmet medical needs.
Mallinckrodt Plc's business model revolves around acquiring and developing branded pharmaceutical products, as well as manufacturing and distributing generic and specialty pharmaceuticals. They aim to address unmet medical needs and improve patient lives through their diverse portfolio of drugs.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Assertio Holdings inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Assertio Holdings inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
